ABSTRACT
Objective: To improve the water solubility and enhance the oral bioavailability of gambogenic acid (GNA). Methods: GNA-phospholipid complex (GNA-PLC) micelles were successfully prepared by anti-solvent method. Results: The encapsulation efficiency of GNA-PLC micelles can reach 99.33 % (w/w). The average particle size of the GNA-PLC micelles was 291.23 nm which was approximate agreed with the transmission electron microscopy (TEM). In vitro release profile showed the GNA-PLC and GNA-PLC micelles have significant sustained-release of GNA compared with crude GNA. Pharmacokinetic parameters indicated that the area under concentration-time curve (AUC0ât) of GNA in cases of GNA-PLC and GNA-PLC micelles are 2.04- and 3.92-fold higher than crude GNA, respectively. Conclusions: The better water solubility and higher bioavailability of GNA in GNA-PLC micelles with significant sustained-release of GNA endow the nanoparticle with great potential in GNA delivery system.
Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Delayed-Action Preparations/chemistry , Micelles , Phospholipids/chemistry , Xanthenes/administration & dosage , Animals , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/pharmacokinetics , Biological Availability , Drug Liberation , Drugs, Chinese Herbal/administration & dosage , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/pharmacokinetics , Female , Garcinia/chemistry , Hep G2 Cells , Humans , Male , Rats, Sprague-Dawley , Solubility , Xanthenes/chemistry , Xanthenes/pharmacokineticsABSTRACT
Norathyriol, an aglycone of mangiferin, is a bioactive tetrahydroxyxanthone present in mangosteen and many medicinal plants. However, the biological fate of norathyriol in vivo remains unclear. In this study, the absorption and metabolism of norathyriol in rats were evaluated through HPLC-MS/MS. Results showed that norathyriol was well absorbed, as indicated by its absolute bioavailability of 30.4%. Besides, a total of 21 metabolites of norathyriol were identified in rats, including methylated, glucuronidated, sulfated and glycosylated conjugates, which suggested norathyriol underwent extensive phase II metabolism. Among those metabolites, 15 metabolites were also identified in hepatocytes incubated with norathyriol, indicating the presence of hepatic metabolism. Furthermore, glucuronide and sulfate conjugates, rather than their parent compound, were found to be the main forms existing in vivo after administration of norathyriol, as implicated by the great increase of exposure of norathyriol determined after hydrolysis with ß-glucuronidase and sulfatase. The information obtained from this study contributes to better understanding of the pharmacological mechanism of norathyriol.
Subject(s)
Xanthenes/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Hepatocytes/metabolism , Male , Rats , Rats, Wistar , Tandem Mass Spectrometry , Xanthones/pharmacokineticsABSTRACT
In this experiment, rat nasal mucosa absorption characteristics of prim-O-glucosylcimifugin and 5-O-methylvisammioside were studied to provide a basis for drug delivery of Toutongning nasal spray. The nasal mucosa absorption test in rats was conducted with in situ nasal perfusion method after pH 6 buffer solution was used to prepare high, medium and low concentrations of prim-O-glucosylcimifugin, 5-O-methylvisammioside mixed solution as liquid circulation in nasal cavity. Then the concentrations of the circulating liquid compositions to be measured were determined by HPLC, and the absorption rates of prim-O-glucosylcimifugin and 5-O-methylvisammioside under different pH conditions were also investigated. According to the results, the absorption rate constant was (0.588±0.041)×10⻳, (0.547±0.023)×10⻳, (0.592±0.063)×10⻳ min⻹ for prim-O-glucosylcimifugin high, middle and low concentrations, and (0.438±0.041)×10⻳, (0.407±0.023)×10⻳, and (0.412±0.063)×10⻳ min⻹ for 5-O-methylvisammioside high, middle and low concentrations. There was no significant difference among high, middle and low concentration groups, and the absorption under pH 6 was better than that under other pH conditions. Therefore, we can get the conclusion that the main active ingredient of Toutongning nasal sprays can be absorbed through the nasal mucosa, and it is feasible to make nasal spray; in addition, pH 6 of nasal spray is scientific and reasonable.
Subject(s)
Drugs, Chinese Herbal/administration & dosage , Monosaccharides/pharmacokinetics , Nasal Mucosa/metabolism , Xanthenes/pharmacokinetics , Administration, Intranasal , Animals , Chromatography, High Pressure Liquid , Drugs, Chinese Herbal/pharmacokinetics , RatsABSTRACT
The poor bioavailability of mangiferin (MGF) is a major obstacle on its further development. Aimed to illustrate the underlying mechanism and improve its poor exposure, the compared PK profiles of MGF and norathyriol (NTR) after different MGF preparation were performed: pure MGF, the Rhizoma Anemarrhenae (Zhi-mu) decoction, MGF, and timosaponin B2 (TB-2) combination. Furthermore, the potential contributing factors, including uridine diphosphoglucuronosyltransferase (UGT), cytochrome P450 (CYP450), P-gp, and enterobacterial were investigated by comparing the PK profiles with and without the corresponding inhibitors or in different rat models. After taking MGF, CYP450 and UGT inhibition could decrease MGF and NTR exposure; P-gp inhibition slightly enhanced (48%) MGF exposure, whereas more apparent for the improved NTR exposure (302%); enterobacterial inhibition almost completely stopped the NTR production, but no such effect was observed for MGF. Compared with the limited improvement by the abovementioned inhibition, the MGF and NTR exposure could significantly increase by 11.5- and 5.9-fold in the Zhi-mu decoction compared with the MGF treatment, probably contributed to TB-2 as an absorption enhancer because the MGF and TB-2 combination produced a similar level of improvement on the PK paremeters of MGF and NTR to the herb treatment. Likewise, most of the effects by UGT, CYP450, P-gp, and enterobacteria followed a similar variation tendency between them. Therefore, the poor bioavailability of MGF possibly mainly attributed to its poor membrane permeability, but not transporters or metabolic enzymes, and the compatibility of MGF and TB-2 could probably expand the prospective application of MGF by improving its bioavailability. © 2016 BioFactors, 42(5):545-555, 2016.
Subject(s)
Drugs, Chinese Herbal/pharmacology , Hypoglycemic Agents/pharmacokinetics , Saponins/pharmacology , Steroids/pharmacology , Xanthenes/pharmacokinetics , Xanthones/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B/metabolism , Administration, Oral , Anemarrhena/chemistry , Animals , Biological Availability , Cytochrome P-450 Enzyme System/metabolism , Drug Evaluation, Preclinical , Drug Synergism , Enterobacteriaceae/metabolism , Gastrointestinal Microbiome , Glucuronosyltransferase/metabolism , Hypoglycemic Agents/administration & dosage , Inactivation, Metabolic , Male , Rats, Wistar , Rhizome/chemistry , Xanthenes/administration & dosage , Xanthones/administration & dosageABSTRACT
Mangiferin (MGF), a glucoside of xanthone existing in phytomedicines and food, is increasingly attracting attention on diabetes treatment, while the underlying mechanism leading to its low oral bioavailability is unclear. Norathyriol (NTR), an active metabolite with hypoglycemic activity and its exposure after MGF dosing remains unclear. Hence, a rapid and sensitive LC-MS/MS method was established and validated to determine MGF and NTR and applied in the PK study in rats. Correspondingly, the in vitro experiments on temperature-dependent uptake, and MGF metabolism in hepatocyte and enterobacteria samples were performed. Results revealed that hepatic first-pass effect slightly contributed to the poor bioavailability of MGF, based on the MGF exposure in portal vein plasma was nearly similar to that in systemic plasma, and the MGF accumulation in the liver was limited, so was that of NTR. Correspondingly, the in vitro study revealed the MGF uptake was mainly dependent on poor passive transport, possibly leading to its limited hepatic metabolism and accumulation. Moreover, the NTR exposure remained considerably low (Cmax < 3 ng/mL, AUCNTR /AUCMGF < 3%) in plasma after single MGF dosing, corresponding to its tiny proportion (0.1%) of MGF in MGF-incubated enterobacteria samples. However, given the low generation and elimination rates of NTR, NTR might accumulate in plasma and exert effects after repeated MGF dosing, although requires further study. This work is the first systemic study on PK profiles of MGF and NTR in vitro and in vivo, which is important for the interpretation on the poor bioavailability and pharmacodynamics of MGF. © 2016 BioFactors, 42(5):533-544, 2016.
Subject(s)
Hypoglycemic Agents/pharmacokinetics , Liver/metabolism , Xanthenes/pharmacokinetics , Xanthones/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Cells, Cultured , Drug Evaluation, Preclinical , Enterobacteriaceae/metabolism , Gastrointestinal Microbiome , Hepatocytes/metabolism , Hypoglycemic Agents/administration & dosage , Male , Primary Cell Culture , Rats, Wistar , Xanthenes/administration & dosage , Xanthones/administration & dosageABSTRACT
Inflammation is a response of body tissues to injury and infection. Compounds that can inhibit inflammation have been shown to have potential therapeutic clinical application. Gambogenic acid (GEA) has potent antitumor and anti-inflammatory activities. Herein, the molecular mechanisms of GEA's anti-inflammatory effect were investigated in lipopolysaccharide (LPS)-stimulated macrophage cells. The results showed that pretreatment with GEA could markedly inhibit interleukin (IL)-1α, IL-1ß, tumor necrosis factor-α, IFN-ß, IL-12b, and IL-23a production in a dose-dependent manner in LPS-induced model. Furthermore, this drug significantly reduced the release of nitric oxide (NO), and impaired the protein level of inducible NO synthase and the cyclooxygenase 2. The finding also showed that the effect of GEA may be related to the suppression of the nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathway. These results indicate that GEA could suppress LPS-simulated inflammatory response partially by attenuating NO synthesis and NF-κB and MAPK activation, suggesting that it may become a potent therapeutic agent for the treatment of inflammatory diseases.
Subject(s)
Inflammation/drug therapy , Macrophages/drug effects , Xanthenes/pharmacokinetics , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cell Line , Cell Survival/drug effects , Cells, Cultured , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Drugs, Chinese Herbal/pharmacology , Humans , Inflammation/metabolism , Inflammation/pathology , Inflammation Mediators/metabolism , Lipopolysaccharides/toxicity , MAP Kinase Signaling System/drug effects , Macrophages/metabolism , Macrophages/pathology , Mice , NF-kappa B/metabolism , Nitric Oxide/biosynthesis , Nitric Oxide Synthase Type II/metabolismABSTRACT
Gambogic acid and gambogenic acid are two major bioactive components of Garcinia hanburyi, and play a pivotal role in biologic activity. In this study, a specific and sensitive liquid chromatography-tandem mass spectrometry was developed and validated for simultaneous determination of gambogic acid and gambogenic acid in rat plasma. Chromatographic separation was achieved on a C18 column using an isocratic elution with methanol-10 m m ammonium acetate buffer-acetic acid (90:10:0.1, v/v/v) as the mobile phase. The detection was performed on a triple-quadrupole tandem mass spectrometer equipped with electrospray positive ionization using multiple reaction monitoring modes. The transitions monitored were m/z 629.3 [M + H](+) â 573.2 for gambogic acid, m/z 631.2 [M + H](+) â 507.2 for gambogenic acid and m/z 444.2 [M + NH4 ](+) â 83.1 for IS. Linear calibration curves were obtained in the concentration range of 2.00-1000 ng/mL for gambogic acid and 0.500-250 ng/mL for gambogenic acid. The lower limits of quantification of gambogic acid and gambogenic acid in rat plasma were 2.00 and 0.500 ng/mL, respectively. The intra- and inter-day precision (RSD) values were <11.7% and accuracy (RE) was -10.6-12.4% at three QC levels for both analytes. The assay was successfully applied to evaluate pharmacokinetics behavior in rats after oral administration of Garcinia hanburyi extracts.
Subject(s)
Chromatography, High Pressure Liquid/methods , Garcinia/chemistry , Plant Extracts/pharmacokinetics , Tandem Mass Spectrometry/methods , Xanthenes/pharmacokinetics , Xanthones/pharmacokinetics , Animals , Male , Plant Extracts/administration & dosage , Plant Extracts/blood , Plasma/chemistry , Rats , Rats, Wistar , Xanthenes/administration & dosage , Xanthenes/blood , Xanthones/administration & dosage , Xanthones/bloodABSTRACT
Astragaloside IV, atractylenolide I, and prim-O-glucosylcimifugin are main medicinal components of the traditional Chinese medicine prescription Yu-ping-feng which is composed of three herbs: Astragalus membranaceus, Atractylodes macrocephala, and Saposhnikovia divaricata. This study is aimed to assess the influence of atractylenolide I and prim-O-glucosylcimifugin on the pharmacokinetic profile of astragaloside IV so as to investigate the pharmacokinetic mechanisms of the Yu-ping-feng prescription. Fifteen Sprague Dawley rats were randomized to three groups; astragaloside IV, astragaloside IV plus atractylenolide I, and a combination of astragaloside IV, atractylenolide I, and prim-O-glucosylcimifugin were respectively administered to rats of these three groups via intragastric gavage. Serum samples were collected at different times after drug administration, and serum concentrations of astragaloside IV and atractylenolide I were simultaneously detected using HPLC-electrospray ionization-MS. Compared with administration of astragaloside IV alone, concentrations of astragaloside IV in the serum were significantly increased when it was given in combination with atractylenolide I or atractylenolide I+prim-O-glucosylcimifugin, with higher values for Cmax (p = 0.019 and p = 0.033 compared with astragaloside IV + atractylenolide I and astragaloside IV + atractylenolide I + prim-O-glucosylcimifugin groups, respectively) and AUC (p = 0.0052 and p = 0.0047 compared with astragaloside IV + atractylenolide I and astragaloside IV + atractylenolide I + prim-O-glucosylcimifugin groups, respectively). Improvement in mean oral Cmax and mean systemic serum exposure because of the pharmacokinetic interaction between astragaloside IV and atractylenolide I might explain the rationale for the use of multiple herbs in Yu-ping-feng and of combinations of A.membranaceus and A. macrocephala.
Subject(s)
Drugs, Chinese Herbal/pharmacokinetics , Lactones/pharmacokinetics , Monosaccharides/pharmacokinetics , Saponins/pharmacokinetics , Sesquiterpenes/pharmacokinetics , Triterpenes/pharmacokinetics , Xanthenes/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Drug Synergism , Drugs, Chinese Herbal/administration & dosage , Lactones/administration & dosage , Lactones/blood , Male , Medicine, Chinese Traditional , Monosaccharides/administration & dosage , Monosaccharides/blood , Rats , Rats, Sprague-Dawley , Saponins/administration & dosage , Saponins/blood , Sesquiterpenes/administration & dosage , Sesquiterpenes/blood , Time Factors , Triterpenes/administration & dosage , Triterpenes/blood , Xanthenes/administration & dosage , Xanthenes/bloodABSTRACT
Study on the effects of Astragali Radix main active flavone calycosin-7-O-ß-D-glucoside on Saposhnikoviae Radix main active ingredients prim-O-glucosylcimifugin and cimifugin, a UPLC-MS/MS method for simultaneous determination of prim-O-glucosylcimifugin and cimifugin in rat plasma was established, and the comparative pharmacokinetics of prim-O-glucosylcimifugin and cimifugin after oral administration of prim-O-glucosylcimifugin and calycosin-7-O-ß-D-glucoside-prim-O-glucosylcimifugin to rats were carried out, which might be conductive in exploring the rationality of Astragali Radix - Saposhnikoviae Radix herb couple. Twelve male SD rats were divided into two groups. Prim-O-glucosylcimifugin and cimifugin in rat plasma of different time points after oral administration of prim-O-glucosylcimifugin and calycosin-7-O-ß-D-glucoside - prim-O-glucosylcimifugin to rats were determinated. And the main pharmacokinetic parameters were investigated using DAS 3. 2. 4. The established method was rapid, accurate and sensitive for simultaneous determination of prim-O-glucosylcimifugin and cimifugin in rat plasma. The analysis was performed on a Waters Acquity BEH C18 column (2.1 mm x 100 mm, 1.7 µm) with the mixture of acetonitrile and 0.1% formic acid/water as mobile phase, and the gradient elution at a flow rate of 0.3 mL x min(-1). The analytes were detected by tandem mass spectrometry with the electrospray ionization (ESI) source and in the multiple reaction monitoring (MRM) mode. Compared with prim-O-glucosylcimifugin group, the AUC(0-t)., and AUC(0-∞) of p-O-glucosylcimifugin as well as the C(max) of cimifugin significantly increased (P < 0.05) in calycosin-7-O-ß-D-glucoside-prim-O-glucosylcimifugin group. Calycosin-7-O-ß-D-glucoside could enhance the absorption of prim-O-glucosylcimifugin and cimifugin and improve the bioavailability, explaining preliminarily the rationality of Astragali Radix-Saposhnikoviae Radix herb couple.
Subject(s)
Chromones/pharmacokinetics , Drugs, Chinese Herbal/pharmacokinetics , Glucosides/pharmacology , Isoflavones/pharmacology , Monosaccharides/pharmacokinetics , Xanthenes/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Chromones/blood , Drug Interactions , Glucosides/blood , Isoflavones/blood , Male , Monosaccharides/blood , Rats , Rats, Sprague-Dawley , Xanthenes/bloodABSTRACT
A sensitive and reliable liquid chromatography-mass spectrometry method has been developed and validated for simultaneous determination of cimifugin and prim-O-glucosylcimifugin in rat plasma after oral administration of Radix Saposhnikoviae (RS) extract, prim-O-glucosylcimifugin monomer solution and cimifugin monomer solution. Plasma samples were pretreated by protein precipitation with acetonitrile containing the internal standards puerarin and daidzein. LC separation was achieved on a Zorbax SB-C(18) column (150 × 4.6 mm i.d., 5 µm) with 0.1% formic acid in water and methanol by isocratic elution. The detection was carried out in select-ion-monitoring mode with a positive electrospray ionization interface. The fully validated method was successfully applied to the pharmacokinetic study of the analytes in rats. A bimodal phenomenon appeared in the concentration-time curve of prim-O-glucosylcimifugin and cimifugin after oral administration of RS extract. Prim-O-glucosylcimifugin mainly transformed to cimifugin when it was absorbed into blood. Both absorption and elimination of cimifugin after oral administration of RS were longer than after administration of single cimifugin. The pharmacokinetic parameters (AUC(0-t) , AUC(0-∞) and t(1/2) ) of prim-O-glucosylcimifugin and cimifugin by giving cimifugin monomer solution, prim-O-glucosylcimifugin monomer solution and RS extract had significant differences (P < 0.05).
Subject(s)
Apiaceae/chemistry , Chromatography, Liquid/methods , Chromones/pharmacokinetics , Drugs, Chinese Herbal/pharmacokinetics , Mass Spectrometry/methods , Monosaccharides/pharmacokinetics , Xanthenes/pharmacokinetics , Administration, Oral , Animals , Chromones/administration & dosage , Chromones/blood , Chromones/chemistry , Drug Stability , Drugs, Chinese Herbal/administration & dosage , Linear Models , Male , Monosaccharides/administration & dosage , Monosaccharides/blood , Monosaccharides/chemistry , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Sensitivity and Specificity , Xanthenes/administration & dosage , Xanthenes/blood , Xanthenes/chemistryABSTRACT
Aminoglycosides enter inner ear hair cells across their apical membranes via endocytosis, or through the mechanoelectrical transduction channels in vitro, suggesting that these drugs enter cochlear hair cells from endolymph to exert their cytotoxic effect. We used zebrafish to determine if fluorescently tagged gentamicin (GTTR) also enters hair cells via apically located calcium-sensitive cation channels and the cytotoxicity of GTTR to hair cells. We then examined the serum kinetics of GTTR following systemic injection in mice and which murine cochlear sites preferentially loaded with systemically administered GTTR over time by confocal microscopy. GTTR is taken up by, and is toxic to, wild-type zebrafish neuromast hair cells. Neuromast hair cell uptake of GTTR is attenuated by high concentrations of extracellular calcium or unconjugated gentamicin and is blocked in mariner mutant zebrafish, suggestive of entry via the apical mechanotransduction channel. In murine cochleae, GTTR is preferentially taken up by the stria vascularis compared to the spiral ligament, peaking 3 h after intra-peritoneal injection, following GTTR kinetics in serum. Strial marginal cells display greater intensity of GTTR fluorescence compared to intermediate and basal cells. Immunofluorescent detection of gentamicin in the cochlea also revealed widespread cellular labeling throughout the cochlea, with preferential labeling of marginal cells. Only GTTR fluorescence displayed increasing cytoplasmic intensity with increasing concentration, unlike the cytoplasmic intensity of fluorescence from immunolabeled gentamicin. These data suggest that systemically administered aminoglycosides are trafficked from strial capillaries into marginal cells and clear into endolymph. If so, this will facilitate electrophoretically driven aminoglycoside entry into hair cells from endolymph. Trans-strial trafficking of aminoglycosides from strial capillaries to marginal cells will be dependent on as-yet-unidentified mechanisms that convey these drugs across the intra-strial electrical barrier and into marginal cells.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Gentamicins/pharmacokinetics , Hair Cells, Auditory/drug effects , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Cell Culture Techniques , Dogs , Dose-Response Relationship, Drug , Fluorescent Dyes/administration & dosage , Fluorescent Dyes/metabolism , Fluorescent Dyes/pharmacokinetics , Gentamicins/administration & dosage , Gentamicins/blood , Hair Cells, Auditory/cytology , Hair Cells, Auditory/metabolism , Injections, Intraperitoneal , Mechanotransduction, Cellular , Mice , Mice, Inbred C57BL , Myosin VIIa , Myosins/deficiency , Stria Vascularis/cytology , Stria Vascularis/drug effects , Stria Vascularis/metabolism , Xanthenes/administration & dosage , Xanthenes/blood , Xanthenes/pharmacokinetics , ZebrafishABSTRACT
Validated analytical methods suitable for determining hyperforin in plasma after administration of alcoholic Hypericum perforatum extracts containing hyperforin are described. After oral administration of 300 mg/kg Hypericum extract (WS 5572, containing 5% hyperforin) to rats maximum plasma levels of approximately 370 ng/ml (approx. 690 nM) were reached after 3 h, as quantified by a HPLC and UV detection method. Estimated half-life and clearance values were 6 h and 70 ml/min/kg respectively. Since therapeutic doses of Hypericum extracts are much lower than that used in rats, a more sensitive LC/MS/MS method was developed. The lower limit of quantification of this method was 1 ng/ml. Using this method, plasma levels of hyperforin could be followed for up to 24 h in healthy volunteers after administration of film coated tablets containing 300 mg hypericum extracts representing 14.8 mg hyperforin. The maximum plasma levels of approximately 150 ng/ml (approx. 280 nM) were reached 3.5 h after administration. Half-life and mean residence time were 9 and 12 h respectively. Hyperforin pharmacokinetics were linear up to 600 mg of the extract. Increasing the doses to 900 or 1200 mg of extract resulted in lower Cmax and AUC values than those expected from linear extrapolation of data from lower doses. Plasma concentration curves in volunteers fitted well in an open two-compartment model. In a repeated dose study, no accumulation of hyperforin in plasma was observed. Using the observed AUC values from the repeated dose study, the estimated steady state plasma concentrations of hyperforin after 3 x 300 mg/day of the extract, i.e., after normal therapeutic dose regimen, was approximately 100 ng/ml (approx. 180 nM).
Subject(s)
Perylene/analogs & derivatives , Quercetin/analogs & derivatives , Xanthenes/pharmacokinetics , Administration, Oral , Adult , Animals , Area Under Curve , Biological Availability , Bridged Bicyclo Compounds , Chromatography, High Pressure Liquid , Female , Half-Life , Humans , Hypericum , Male , Perylene/chemistry , Perylene/pharmacokinetics , Phloroglucinol/analogs & derivatives , Plant Extracts/pharmacokinetics , Plants, Medicinal , Quercetin/chemistry , Quercetin/pharmacokinetics , Rats , Rats, Sprague-Dawley , Terpenes/analysis , Terpenes/blood , Terpenes/pharmacokinetics , Xanthenes/chemistryABSTRACT
In the present study, the mechanism involved in the enhancement of adriamycin (ADR) accumulation by cepharanthin (CEP) and hyperthermia were examined. The accumulation of ADR and Fluo3 (an indicator of Ca2+) was increased by treatment with CEP. This suggests that ADR accumulation may increase due to increased influx of Ca2+. The ADR accumulation increased with increasing the KCl concentration in the presence of CEP when the KCl concentration was over 200 mM. This demonstrates that ADR accumulation increases with treatment with CEP and increasing the KCl concentration after the cell membrane potential reaches 0. ADR accumulation did not change with the extracellular pH in the absence of NaHCO3. CEP increased the ADR accumulation with increasing extracellular pH, regardless of NaHCO3. This suggests that CEP may affect the H+ flux, and consequently increase ADR accumulation regardless of NaHCO3. Further, it increased with increasing extracellular pH in the presence of NaHCO3, regardless of CEP. It is thought that the interaction between H+ and HCO3- may cause increased ADR accumulation. ADR accumulation was decreased by DIDS and amiloride at 37 degrees C. ADR accumulation in the presence of amiloride at 45 degrees C was increased compared with that at 37 degrees C. However, the accumulation combined with amiloride and hyperthermia was lower than with treatment with ADR only at 37 degrees C. This indicates that ADR accumulation is decreased by amiloride and increased by hyperthermia. ADR accumulation is further decreased by DIDS at 45 degrees C compared with 37 degrees C. This suggests that the H+ flux in hyperthermia is influenced by Cl-/HCO3- exchanger but not Na+/H+ exchanger.
Subject(s)
Alkaloids/pharmacology , Aniline Compounds/pharmacokinetics , Antineoplastic Agents, Phytogenic/pharmacology , Calcium/metabolism , Carcinoma, Ehrlich Tumor/metabolism , Doxorubicin/pharmacokinetics , Hyperthermia, Induced , Xanthenes/pharmacokinetics , Animals , Benzylisoquinolines , Biological Transport/drug effects , Chlorides/pharmacology , Doxorubicin/toxicity , Drug Resistance, Neoplasm , Fluorescent Dyes , Hot Temperature , Ionomycin/pharmacology , Kinetics , Manganese Compounds/pharmacology , Mice , Potassium Chloride/pharmacology , Tumor Cells, CulturedABSTRACT
Stimulus-induced changes in free cytosolic Ca2+ in different types of plant cells have been monitored with the aid of fluorescent calcium indicator dyes. However, there is no simple and convenient method for introducing these dyes into the plant cell cytoplasm. This paper reports tests of different procedures for loading either free fluorescent dyes or their acetoxymethyl esters (Fluo-3 and Fluo-3/AM, respectively) into Sinapis alba root tissue. Loading of Fluo-3 was pH and temperature dependent. Moreover, in the presence of beta-escin (saponin) in the loading medium very high fluorescent signals in root tissues were observed. The highest signals were recorded when tissue was loaded in a medium containing 0.1% beta-escin, at pH 5.0 and 30 degrees C. Only very weak fluorescence signals were found in mustard roots loaded with Fluo-3/AM. Acidity and temperature of the medium had no significant effect on the process. However, addition of eserine, a cholinesterase inhibitor led to a dramatic increase in fluorescence in the root cells. On the basis of these observations rapid and efficient methods of loading both Fluo-3 and Fluo-3/AM into mustard root tissues are proposed.
Subject(s)
Aniline Compounds/pharmacokinetics , Calcium/analysis , Fluorescent Dyes/pharmacokinetics , Mustard Plant/chemistry , Plant Roots/chemistry , Plants, Medicinal , Xanthenes/pharmacokinetics , Acetylcholinesterase/analysis , Aniline Compounds/analysis , Biological Transport/drug effects , Bromine/pharmacology , Calcimycin/pharmacology , Cholinesterase Inhibitors/pharmacology , Escin/pharmacology , Fluorescent Dyes/analysis , Hydrogen-Ion Concentration , Ionophores , Manganese/pharmacology , Microscopy, Confocal , Physostigmine/pharmacology , Plant Proteins/analysis , Plant Roots/drug effects , Plant Roots/enzymology , Poloxalene/pharmacology , Surface-Active Agents/pharmacology , Temperature , Xanthenes/analysisABSTRACT
The single- and multiple-dose pharmacokinetics of the naphthodianthrones hypericin and pseudohypericin derived from St. John's wort (Hypericum perforatum, LI 160, Lichtwer Pharma GmbH, Berlin) were studied in 12 healthy male subjects. After a single oral dose of 300, 900, or 1800 mg of dried hypericum extract (250, 750, or 1500 micrograms hypericin and 526, 1578, or 3156 micrograms pseudohypericin), plasma levels were measured with a modified highly sensitive high-pressure liquid chromatography (HPLC) method (lower detection limit 0.1 ng/mL) up to 3 days. The median maximal plasma levels were 1.5, 4.1, and 14.2 ng/mL for hypericin and 2.7, 11.7, and 30.6 ng/mL for pseudohypericin, respectively, for the three doses given above (interim evaluation of four volunteers). The median elimination half-life times of hypericin were 24.8 to 26.5 hours, and varied for pseudohypericin from 16.3 to 36.0 hours. Ranging between 2.0 to 2.6 hours, the median lag-time of absorption was remarkably prolonged for hypericin when compared to pseudohypericin (0.3 to 1.1 hours). The areas under the curves (AUC) showed a nonlinear increase with raising dose; this effect was statistically significant for hypericin. During long-term dosing (3 x 300 mg/day), a steady-state was reached after 4 days. Mean maximal plasma level during the steady-state treatment was 8.5 ng/mL for hypericin and 5.8 ng/mL for pseudohypericin, while mean trough levels were 5.3 ng/mL for hypericin and 3.7 ng/mL for pseudohypericin. In spite of their structural similarities there are substantial pharmacokinetic differences between hypericin and pseudohypericin.